Spero Therapeutics, Inc. (SPRO)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Spero Therapeutics, Inc. (SPRO)
Go deeper and ask any question about SPRO
Company Performance
Current Price
as of Sep 13, 2024$1.37
P/E Ratio
4.08
Market Cap
$74.05M
Description
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.
Metrics
Overview
- HQCambridge, MA
- SectorHealth Technology
- IndustryBiotechnology
- TickerSPRO
- Price$1.37+3.01%
Trading Information
- Market Cap$74.05M
- Float71.90%
- Average Daily Volume (1m)125,476
- Average Daily Volume (3m)118,497
- EPS$0.34
Company
- Revenue$105.43M
- Rev Growth (1yr)663.58%
- Net Income-$17.86M
- Gross Margin99.97%
- EBITDA Margin-386.22%
- EBITDA-$23.24M
- EV$11.56M
- EV/Revenue0.11
- P/E4.08
- P/S0.70
Documents
SEC Filings
Earnings Calls
Factset Street Account